Abstract: The present invention relates to a mucoadhesive layer, preferably mucoadhesive buccal layer, comprising a non-nanoparticulate macrolide. Furthermore, the present invention relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer comprising a non-nanoparticulate macrolide, and further comprising a backing layer. The present invention also relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer, a backing layer, and an intermediate layer. The present invention further relates to a mucoadhesive layer or mucoadhesive film for use as a medicament and for use in preventing and/or treating transplant rejection. Moreover, the present invention relates to a method of preparing a mucoadhesive film.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: A method for producing a liposome dispersion comprising at least one amphiphilic lipid, wherein the method comprises the steps of: providing a first stream (a) comprising an organic solvent, providing a second stream (b) comprising water, wherein at least one of first stream (a) and second stream (b) comprises the at least one amphiphilic lipid, ejecting the first stream (a) and the second stream (b) through pinholes, and frontally colliding the first stream (a) and the second stream (b), whereby the liposome dispersion comprising the at least one amphiphilic lipid is obtained.

Abstract: The present invention relates to a mucoadhesive layer, preferably mucoadhesive buccal layer, comprising a non-nanoparticulate macrolide. Furthermore, the present invention relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer comprising a non-nanoparticulate macrolide, and further comprising a backing layer. The present invention also relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer, a backing layer, and an intermediate layer. The present invention further relates to a mucoadhesive layer or mucoadhesive film for use as a medicament and for use in preventing and/or treating transplant rejection. Moreover, the present invention relates to a method of preparing a mucoadhesive film.

Abstract: The present invention describes a method for producing nanoparticles, wherein the nanoparticles contain or consist of hydroxypropyl methylcellulose acetate succinate (HPMCAS), and wherein i) HPMCAS is dissolved in an organic solvent in order to obtain an organic solution and ii) the organic solution is mixed with water to precipitate the nanoparticles in order to obtain precipitated nanoparticles and a mixed liquid phase as well as nanoparticles obtained by that method.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: Nanoparticles including tacrolimus, and a method for providing nanoparticles including tacrolimus as well as to nanoparticles including tacrolimus that are obtainable by said method. Also relates to the nanoparticles including tacrolimus for use as a medicament. Further relates to a mucoadhesive buccal film containing the nanoparticles including tacrolimus and the mucoadhesive buccal film for use as a medicament, especially in pediatric patients.

Abstract: The present invention provides nanoparticles comprising at least one boronic acid compound and at least one stabilizing agent for the at least one boronic acid compound and/or a reaction product of the at least one boronic acid compound and the at least one stabilizing agent, whereby the nanoparticles have a particle size of about 10 to about 1000 nm. The present invention also provides a pharmaceutical composition comprising these nanoparticles and a method for the preparation of these nanoparticles and the respective pharmaceutical compositions. In addition, the present invention provides nanoparticles and pharmaceutical compositions for the treatment of several disorders, especially multiple myeloma, preferably by parenteral administration.

Abstract: An analyte test element for the qualitative and/or quantitative determination of at least one analyte in a physiological or aqueous sample fluid having a first surface (2a) and a second surface (4a) in a predetermined distance opposite from each other, said both surfaces are provided with two substantially equivalent patterns forming areas of high and low surface energy which are aligned mostly congruent, whereby the areas of high surface energy (6, 6?) create a sample distribution system with at least two detection areas (6a, 6?a), said at least one of the detection areas (6a, 6?a) of the first and second surfaces (2a, 4a) is provided with at least one non-enzymatic recognition element (32).

Abstract: A test element for the determination of coagulation in a plasma or whole blood sample having a first surface (2a) and a second surface (4a) in a predetermined distance opposite from each other, said both surfaces being provided with two substantially equivalent patterns forming areas of high and low surface energy which are aligned mostly congruent, whereby the areas of high surface energy create a sample distribution system (6) with at least one detection area (6a), wherein the detection area(s) (6a, 6?a) of the first and second surfaces (2a, 4a) is/are provided with at least one coagulation stimulation reagent. The coagulation test element is provided with an integrated quality control system suitable for dry reagent test strip format with a very small sample volume of about 0.5 ?L. The production of the inventive coagulation test element involves only a small number of uncomplicated production steps enabling an inexpensive production of the element.